ABSTRACT OBJECTIVES The Registry of the Utilization of the TAo-TAVR approach using the Edwards SAPIEN Valve (ROUTE) was established to assess the effectiveness and safety of the use of transaortic (TAo) access for transcatheter aortic valve replacement (TAVR) procedures (NCT01991431).
However, each of the approaches is associated with advantages and disadvantages resulting in different TAVR-related complications (10) (11) (12) (13) (14) . Because the majority of studies regarding TAo-TAVR using the SAPIEN transcatheter heart valve have been singlecenter case series and have included relatively low numbers of patients, there is a need to confirm morbidity and mortality outcomes by evaluating a large, multinational population (3, 6, 9, 15) .
With the aim of meeting this need, the ROUTE (Registry of the Utilization of the TAo-TAVR approach using the Edwards SAPIEN Valve) was established (16). This is a multicenter, international, prospective registry that included patients who received either the SAPIEN XT or the SAPIEN 3 valves (Edwards Lifesciences, Irvine, California) via TAo. The primary aim of the study was to assess overall mortality during a 30-day follow-up. Further, procedural characteristics, complications, and TAVR-related mortality were investigated. Bapat et al.
METHODS
Transaortic access for TAVR S E P T E M B E R 1 2 , 2 0 Values are n/N (%).
TA ¼ transapical; TF ¼ transfemoral; other abbreviations as in Table 1 . Values are mean AE SD or n/N (%). Intensive care unit stay, days 2.8 AE 5.6
Hospital stay, days 9.9 AE 8.5
Values are n/N (%) or mean AE SD. *Procedural success defined as deployment of one Edwards SAPIEN valve without need for a second valve, no conversion to conventional surgery, and no intraprocedural death. ‡For 3 patients, we were unable to obtain information on valve delivery and catheter retrieval, making 98.7% the worst case.
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Transaortic access for TAVR S E P T E M B E R 1 2 , 2 0 1 6 : 1 8 1 5 -2 2 complications included myocardial infarction (1.0%), stroke (1.0%), transient ischemic attack (0.3%), major vascular complications (3.4%), life-threatening bleeding (3.4%), and acute kidney injury (9.5%). A total of 8.8% of patients required permanent pacemaker implantation during the follow-up period.
Rehospitalization for valve-related symptoms or deterioration occurred in 3.4% of patients ( Table 6) . Values are mean AE SD or n/N (%).
NYHA ¼ New York Heart Association (33); other abbreviation as in Table 1 . Table 1 . underwent conversion to conventional surgery (15) .
The values noted in the present registry are generally comparable to those previously reported for TF-TAVR (1.1% to 2.4% for a second valve; 0.8% to 1.7% for conversion to conventional surgery) (14, (25) (26) (27) (28) , and for the TA route (0.7% to 2.8% for a second valve;
1.0% to 3.9% for conversion to conventional surgery) (14, 21, 24, (26) (27) (28) . No deaths occurred during the TAo-TAVR procedures included in the present registry, which is in agreement with the low numbers reported in other studies (6, 9, 15, 24) .
There were very few access complications found when using the TAo-TAVR procedure. This is likely due to the familiarity of surgeons with aortic interventions. In comparison, ventricular damage and bleeding have been previously associated with the TA access route (14, 15, 20, 29) . Furthermore, the occurrence of arterial injury when using the TF route is notable (14, 30, 31) . (14, 15, 24, 26, 27) , whereas published values associated with use of TF access are 8.0% to 11.1% (14, 26, 31, 32) . In the present registry, cardiovascular mortality at 30 days was found to be 4.4%, with TAVR-related mortality being 3.1%. Lardizabal et al. (15) reported cardiovascular mortality of 2.0% for TAo-TAVR, whereas the value documented for TA access was higher at 12.0%. Kingdom. E-mail: vnbapat@yahoo.com.
